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ABSTRACT 
A series of triazole (6a-f) and tetrazole (7a-f) derivatives were synthesized and their structures were confirmed by IR, 1HNMR and mass 
spectroscopic studies. All the compounds have been screened for their antibacterial activity against Staphylococcus aureus, Pseudomonas aeruginosa 
and Escherichia coli and antifungal activity against Aspergillus fumigates Aspergillus niger and Candida albicans. Evaluation of antimicrobial activity 
considering the MIC value calculated by the serial dilution method revealed that several compounds exhibits good to moderate activity. Further to 
understand the interaction of the compounds with the bacterial and fungal protein receptor binding sites, docking studies are  conducted using biotin 
protein ligase (BPL) (3V7R) from Staphylococcus aureus and dihydrofolate reductase (DHFR) (PDB ID 4HOF) from Candida albicans. Among the all 
compounds, compound 6d of triazole derivative and compound 7f of tetrazole derivative showed high docking energy. This investigation has open up 
the scope for development of a new class of antimicrobial agents. 
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INTRODUCTION 
The expanding microbial resistance to currently available 
antimicrobial drugs has grown into a serious human health 
complication and is the major cause of morbidity and mortality 
throughout the world. Infections bring about by these resistant 
microorganisms such as bacteria, fungi parasites and viruses decline the 
relevant common medications, resulting in persistence and spreading of 
infections [1-3]. Most of these microbes are the human pathogens 
accompanying the surrounding habitat, may be allied to the progress of 
these severe infections with continued illness and greater risk of deaths. 
The most prevailing are the bacterial and fungal pathogens, for the most 
part associate with hospital and community-acquired infections 
primarily in immunocompromised conditions. They are liable for 
common infections of urinary tract, bloodstream, skin and pneumonia to 
high percentage of hospital acquired infectious diseases, especially 
among patients immunocompromised due to AIDS, diabetic, organ 
transplantation, severe burns, chemotherapy or other invasive 
procedures [1, 3-6]. Despite the availability of large number of 
antimicrobials for clinical use and their resistance against some fungal 
and bacterial strains, the emergence in the designing new, more 
effective, and safe antimicrobial agents has opened up an intense 
research for medicinal chemists. These efforts are mainly implemented 
for controlling not only serious infections, but also the prevention and 
treatment of complications associated with infections of other 
therapeutic modalities such as cancer chemotherapy and surgery. 
Besides developing completely new agents with chemical characteristics 
that clearly differ from those of existing ones, the combination therapy  
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is another approach fusing two or more biologically active 
heterocyclic systems to a single molecular scaffold. In this context, the 
pharmacologically important azole derivatives possessing diverse 
activity are of intense research in the antimicrobial therapy [1, 3, 7, 8]. 
The five membered azoles are heterocyclic compounds with 
two or more heteroatoms in which at least one is nitrogen. Their natural 
existence provides a source for wider biological applications in treating 
various diseases and is mainly considered as integral structural feature 
for the synthesis and development of new medicinal agents. Research on 
these azole heterocycles, especially triazole-tetrazole chemistry, has 
gained considerable interest owing to their pharmacological importance 
as antimicrobial, analgesic, anti-inflammatory, anticancer, 
anticonvulsant and antimalarial agents. As a result, a variety of new 
improved compounds are established varying the substitution on the 
triazole and tetrazole nucleus [7-9]. The importance of triazole derivatives 
lie in the field that these have occupied a unique position in heterocyclic 
chemistry due to their agricultural, industrial, and biological activities, 
along with the application of the concept of “click-synthesis” for their 
efficient and quick synthesis [10-12]. Triazoles have also been 
incorporated in a wide variety of therapeutically interesting drugs 
including H1/H2 histamine receptor blockers, CNS stimulants, anti-
anxiety agents and sedatives. The 1,2,3- triazole system has been well 
reported with wide spread uses of antitubercular, antimalarial, 
analgesic, antimicrobial, local anaesthetic, antineoplastic, 
antiinflammatory, anticonvulsant, antiviral, antiproliferative, anticancer 
and antioxidant activities [13-21]. This triazole moiety is stable to 
metabolic degradation and capable of hydrogen bonding, which could be 
favourable in binding bimolecular targets as well as increasing 
solubility. Moreover, they can function as attractive linker units which 
could connect two pharmacophores to give some innovative 
bifunctional drugs, thus have become increasingly useful and important 
in constructing bioactive and functional molecules [10, 12, 22-25]. 
On the other hand, Tetrazoles are class of synthetic organic 
heterocyclic compounds, possessing broad spectrum of activities in 
major areas such as medicine, agriculture and imaging technology, and 
are very stimulating heterocycles from an academic viewpoint [26-31].  In 
general, this nitrogen rich ring system is used in propellants, explosives, 
and in pharmaceuticals. In addition, tetrazoles are important synthons 
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in synthetic organic chemistry and also used as precursors of carbenes 
in flash vacuum pyrolysis. Tetrazole, an aromatic azapyrrole group, is 
metabolically stable and has acidic characteristics closely similar to that 
of the carboxylic group. Various tetrazole based compounds have also 
shown good coordination properties and are able to form stable 
complexes with several metal ions. Furthermore, the tetrazole ring has 
strong electron withdrawing property, have been successfully used in 
organic synthesis as derivatising agents for the chemical modification 
[32-36]. Tetrazoles are incorporated in a large number of drugs to achieve 
a wide spectrum of biological activities and their derivatives have been 
reported as antibacterial, antifungal, antiviral, herbicidal, antitumor, 
anticonvulsant, analgesic, antiinflammatory, antitubercular, anticancer 
and antihypertensive activities [37-43]. 
                 In view of these considerations, in the present study a new 
series of triazole and tetrazole derivatives were synthesized and 
evaluated for in vitro antimicrobial activities. 
Chemistry: 
Scheme-1:  
 
Scheme-2 
 
6a R1= Ethyl; 6b R1= Propyl; 6c R1= Butyl; 6d R1= Pentyl; 6e R1= Isopropyl; 6f R1= Isobutyl 
7a R2= H; 7b R2= Ethyl; 7c R2= Propyl; 7d R2= Butyl; 7e R2= Isopropyl; 7f R2= Isobutyl 
General procedure for synthesis: 
1. Synthesis of alkyl azides (a-f): 
Sodium azide reacted with alkyl bromide (a-f) at reflux 
temperature in water: THF solvent system for 3 hr to yield 
corresponding alkyl azides (a-f). The N3 peak of alkyl azides (a-f) 
observed in the IR spectrum in the range of 2082-2116 cm-1. 
Synthesis of 4-(Benzoxazole-2-yl)phenol (3):  
 o-Amino phenol (1) (2.18g, 20mmol) and p-hydroxy benzoic 
acid (2) (3.32g, 24mmol) were taken in a round bottom flask in xylene 
(90ml) refluxed for 12hr by adding p-toluenesulfonic (21.00g, 50mmol). 
Ethyl acetate (180ml) was added to the mixture, and then washed with 
saturated sodium bicarbonate solution. The organic phase was dried 
over Na2SO4 and filtered. The filtrate crude product was purified by 
column with pet ether: ethyl acetate (80:20) to get 4-(Benzoxazole-2-
yl)phenol (3) [44]. 
2. Synthesis of 2-(4-(prop-2-yn-1-yloxy) phenyl) benzo[d]oxazole (4): 
 4-(Benzoxazole-2-yl)phenol (3) (2.0g, 9.0mmol) dissolved in 
dry acetone and refluxed over anhydrous potassium carbonate for 6hrs 
on water bath by adding propargyl bromide (1.05ml, 9.0mml). After 
completion of the reaction was monitored by TLC acetone was removed 
under reduced pressure and crushed ice was added to the residue. The 
product 2-(4-(prop-2-yn-1-yloxy)phenyl)benzo[d]oxazole (4) was 
filtered washed with water and recrystallized from chloroform. 
3. 2-(4-(benzo[d]oxazol-2-yl)phenoxy)acetonitrile (5): 
4-(benzo[d]oxazol-2-yl)phenol (3) (2.0g, 9.0mmol) and 
Chloroacetonotrile (0.67ml, 9.0mmol) were dissolved in dry acetone 
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and refluxed over anhydrous potassium carbonate for 3hrs on water 
bath to get the products 2-(4-(benzo[d]oxazol-2-yl)phenoxy) 
acetonitrile (5) which was purified on column chromatography with 
pet.ether:ethylacetate (80:20) gave as white solid. 
4. 2-(4-((1-alkyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)benzo[d] 
oxazole (6a-f): 
2-(4-(prop-2-yn-1-yloxy)phenyl)benzo[d]oxazole (4) (2.0g, 
8.03mmol) and equimoles of alkyl azides (a-f) were suspended in 1:1 
mixture of water and tertiary butanol followed by freshly prepared 1M 
sodium ascorbate solution in water and copper sulphate in water was 
added. The heterogeneous reaction mixture was stirred for 6-9 hr at 
room temperature to yield 2-(4-((1-ethyl-1H-1,2,3-triazol-4-yl) 
methoxy)phenyl)benzo[d]oxazole (6a). 
2-{4-[(1-ethyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-1,3-
benzoxazole (6a): 
IR (KBr): υ 1733 (C=C of triazole), 1609 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.61-7.76 δ (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-
H), 7.24 (s, 1H, 5ꞌꞌ-H), 6.92-7.04 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.26 (s, 2H, -
OCH2), 3.76 (q, 2H, J=7.6Hz, 1ꞌꞌ-CH2), 1.20 δ (t, 3H, J=7.6Hz, 2ꞌꞌꞌ-CH3). 13C-
NMR (CDCl3, 100MHz): δ 160.9 (C-2), 158.4 (C-4ꞌ), 149.1 (C-7a), 140.9 
(C-4ꞌꞌ), 140.2 (C-4), 126.2 (C-5ꞌꞌ), 123.3 (C-5), 122.2 (C-6), 121.4 (C-1ꞌ), 
117.4 (C-3a), 114.1 (C-2ꞌ, C-6ꞌ), 113.2 (C-3ꞌ, C-5ꞌ), 109.8 (C-7), 71.0 (-
OCH2), 48.1 (C-1ꞌꞌꞌ), 13.6 (C-2ꞌꞌꞌ). Mass (ES): m/z 321.1 [M+H]+, M.P: 172 
0C, Yield: 72 %. 
2-{4-[(1-propyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-1,3-
benzoxazole (6b): 
IR (KBr): υ 1728 (C=C of triazole), 1605 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.72-7.83 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 
7.28 (s, 1H, 5ꞌꞌ-H), 6.96-7.07 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.29 (s, 2H, -
OCH2), 3.81 (t, 2H, J=7.2Hz, 1ꞌꞌ-CH2), 1.82-1.93 (m, 2H, 2ꞌꞌꞌ-CH2), 1.09 (t, 
3H, J=7.2Hz, 3ꞌꞌꞌ-CH3). 13C-NMR (CDCl3, 100MHz): δ 161.9 (C-2), 159.3 (C-
4ꞌ), 151.1 (C-7a), 141.2 (C-4ꞌꞌ), 140.6 (C-4), 126.2 (C-5ꞌꞌ), 122.8 (C-5), 
121.7 (C-6), 120.4 (C-11), 117.0 (C-3a), 114.3 (C-2ꞌ, C-6ꞌ), 113.0 (C-3ꞌ, C-
5ꞌ), 109.8 (C-7), 70.0 (-OCH2), 49.1 (C-1ꞌꞌꞌ), 19.5 (C-2ꞌꞌꞌ), 12.0 (C-3ꞌꞌꞌ). Mass 
(ES): m/z 335.1 [M+H]+, M.P: 186 0C, Yield: 70 %. 
2-{4-[(1-butyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-1,3-
benzoxazole (6c): 
IR (KBr): υ 1682 (C=C of triazole), 1598 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.66-7.81 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 
7.26 (s, 1H, 5ꞌꞌ-H), 6.93-7.06 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.27 (s, 2H, -
OCH2), 3.80 (t, 2H, J=7.6Hz, 1ꞌꞌꞌ-CH2), 1.84-1.96 (m, 2H, 2ꞌꞌꞌ-CH2), 1.29-
1.37 (m, 2H, 3ꞌꞌꞌ-CH2), 1.01 (t, 3H, J=7.2Hz, 3ꞌꞌꞌ-CH3). 13C-NMR (CDCl3, 
100MHz): δ 160.0 (C-2), 158.2 (C-4ꞌ), 149.6 (C-7a), 141.2 (C-4ꞌꞌ), 140.1 
(C-4ꞌꞌ, 139.2 (C-4), 125.8 (C-5ꞌꞌ), 123.2 (C-5), 120.6 (C-1ꞌ), 117.0 (C-3a), 
113.7 (C-2ꞌ, C-6ꞌ), 113.0 C-3ꞌ, C-5ꞌ), 108.7 (C-7), 71.3 (-OCH2), 48.4 (C-1ꞌꞌꞌ), 
28.2 (C-2ꞌꞌꞌ), 19.0 (C-3ꞌꞌꞌ), 14.6 (C-4ꞌꞌꞌ). Mass (ES): m/z 349.6 [M+H]+, M.P: 
176 0C, Yield: 84 %. 
2-{4-[(1-pentyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-1,3-
benzoxazole (6d): 
IR (KBr): υ 1696 (C=C of triazole), 1602 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.69-7.80 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 
7.28 (s, 1H, 5ꞌꞌ-H), 6.95-7.07 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.29 (s, 2H, -
OCH2), 3.82 (t, 2H, J=7.6Hz, 1ꞌꞌꞌ-CH2), 1.86-1.95 (m, 2H, 2ꞌꞌꞌ-CH2), 1.27-
1.38 (m, 2H, 3ꞌꞌꞌ-CH2), 0.89 (t, 3H, J=7.2Hz, 5ꞌꞌꞌ-CH3). 13C-NMR (CDCl3, 
100MHz): δ 161.0 (C-2), 159.3 (C-4ꞌ), 151.3 (C-7a), 141.3 (C-4ꞌꞌ), 127.1 
(C-5ꞌꞌ), 122.9 (C-5), 121.9 (C-6), 120.8 (C-1ꞌ), 120.6 (C-1ꞌ), 117.4 (C-3a), 
114.7 (C-2ꞌ, C-6ꞌ), 113.0 (C-3ꞌ, C-5ꞌ), 109.5 (C-7), 70.6 (-OCH2), 49.7 (C-
1ꞌꞌꞌ), 29.9 (C-2ꞌꞌꞌ), 27.8 (C-3ꞌꞌꞌ), 18.7 (C-4ꞌꞌꞌ), 11.9 C-5ꞌꞌꞌ). Mass (ES): m/z 
363.8 [M+H]+, M.P: 158 0C, Yield: 88 %. 
 
2-(4-{[1-(propan-2-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-1,3-
benzoxazole (6e): 
IR (KBr): υ 1678 (C=C of triazole), 1594 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.63-7.78 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 
7.24 (s, 1H, 5ꞌꞌ-H), 6.92-7.05 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.27 (s, 2H, -
OCH2), 4.08- δ 4.22 (m, 1H,1ꞌꞌꞌ-CH), 1.67 (d, H, J=6.8Hz, 2ꞌꞌꞌ-(CH3)2). 13C-
NMR (CDCl3, 100MHz): δ 160.7 (C-2), 158.9 (C-4ꞌ), 149.5 (C-7a), 140.6 
(C-4ꞌꞌ), 139.7 (C-4), 125.9 (C-5ꞌꞌ), 123.2 (C-5), 122.3 (C-6), 120.9 (C-1ꞌ), 
117.3 (C-3a), 13.8 (C-2ꞌ, C-6ꞌ), 113.1 (C-3ꞌ, C-5ꞌ), 108.9 (C-7), 71.5 (-
OCH2), 52.8 (C-1ꞌꞌꞌ), 32.4 (C-2ꞌꞌꞌ). Mass (ES): m/z 335.2 [M+H]+, M.P: 164 
0C, Yield: 82 %. 
2-(4-{[1-(2-methylpropyl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-
1,3-benzoxazole (6f): 
IR (KBr): υ 1676 (C=C of triazole), 1602 (C=N of benzaxazole) 
cm-1. 1H-NMR (CDCl3, 400MHz): δ 7.72-7.84 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 
7.25 (s, 1H, 5ꞌꞌ-H), 6.97-7.07 (m, 4H, 4-H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.28 (s, 2H, -
OCH2), 3.87 (d, 2H, J=6.8Hz, 3ꞌꞌꞌ (CH3)2), 1.28 (d, 2H, J=6.8Hz, 3ꞌꞌꞌ-(CH3)2), 
4.08-4.22 (m, 1H, 1ꞌꞌꞌ-CH), 1.67 (d, H, J=6.8Hz, 2ꞌꞌꞌ-(CH3)2). 13C-NMR 
(CDCl3, 100MHz): δ 160.9 (C-2), 159.1 (C-4ꞌ), 150.2 (C-7a), 141.6 (C-4ꞌꞌ), 
140.1 (C-4), 127.2 (C-5ꞌꞌ), 123.4 (C-5), 122.1 (C-6), 121.9 (C-1ꞌ), 117.3 (C-
3a), 117.6 (C-2ꞌ, C-6ꞌ), 112.7 (C-3ꞌ, C-5ꞌ), 109.2 (C-7), 70.8 (-OCH2), 46.6 
(C-1ꞌꞌꞌ), 22.7 (C-2ꞌꞌꞌ), 13.8 (C-3ꞌꞌꞌ). Mass (ES): m/z 349.6 [M+H]+, M.P: 142 
0C, Yield: 78 %. 
2-(4-((2H-tetrazol-5-yl) methoxy) phenyl) benzo[d]oxazole (7a): 
A mixture of 2-(4-(benzo[d]oxazol-2-yl)phenoxy)acetonitrile 
(5) (2.0g, 8.0mmol), sodium azide (0.52g, 8.0mmol) and NH4Cl (0.42g, 
8.0mmol) in DMF (15ml) was heated for 8hr at 1200C. The reaction 
mixture was cooled to room temperature and added crushed ice, and 
then a cream colour precipitate was obtained. It was collected by 
filtration and washed with water, dried at 500C to get crude compound 
which was purified on column chromatography with pet. ether: 
ethylacetate (70:30) gave as  (7a) as light cream solid.  
2-{4-[(2H-tetrazol-5-yl)methoxy]phenyl}-1,3-benzoxazole (7a): 
IR (KBr): υ 1661 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.76-7.88 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.95-7.08 (m, 4H, 4-
H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.21 (s, 2H, -OCH2). 13C-NMR (CDCl3, 100MHz): δ 
161.0 (C-2), 159.6 (C-5ꞌꞌ), 113.1 (C-2ꞌ, C-6ꞌ), 159.2 (C-4ꞌ), 112.4 (C-3ꞌ, C-
5ꞌ), 148.3 (C-7a), 109.7 (C-7), 137.4 (C-3a), 69 (-OCH2), 121.9 (C-5), 
120.4 (C-6), 119.8 (C-1ꞌ), 118.4 (C-4). Mass (ES): m/z 294.10 [M+H]+, 
M.P: 258 0C, Yield: 68 %. 
 
2-(4-((2-alkyl-2H-tetrazol-5-yl) methoxy) phenyl) benzo[d]oxazole 
(7b-f): 
 2-(4-((2H-tetrazol-5-yl)methoxy)phenyl)benzo[d]oxazole 
(7a) (1g, 3.41mmol) dissolved in dry acetone and Ethyl bromide 
(0.36ml, 3.41mmol) was added, refluxed over anhydrous potassium 
carbonate for 3 hrs on water bath. Reaction was monitored by TLC, 
acetone was removed under reduced pressure and crushed ice was 
added to the residue, compound was filtered and washed with plenty of 
water. The compounds were purified on column chromatography with 
pet. ether: ethylacetate (85:15) gave 2-(4-((2-alkyl-2H-tetrazol-5-yl) 
methoxy)phenyl)benzo[d]oxazole (7b) as white solid. 
2-{4-[(2-ethyl-2H-tetrazol-5-yl)methoxy]phenyl}-1,3-benzoxazole 
(7b): 
IR (KBr): υ 1672 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.76-7.81 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.95-7.08 (m, 4H, 4-
H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.23 (s, 2H, -OCH2), 3.44 (q, 2H, J=7.2Hz, 1ꞌꞌꞌ-CH2), 1.22 
(t, 3H, J=7.2 Hz, 2ꞌꞌꞌ-CH3). 13C-NMR (CDCl3, 100MHz): δ 161.8 (C-2), 160.1 
(C-5ꞌꞌ), 113.5 (C-2ꞌ, C-6ꞌ), 159.8 (C-4ꞌ), 112.9 (C-3ꞌ, C-5ꞌ), 149.3 (C-7a), 
110.0 (C-7), 136.8 (C-3a), 69.2 (-OCH2), 121.3 (C-5), 52.7 (C-1ꞌꞌꞌ), 120.4 
(C-6), 13.4 (C-2ꞌꞌꞌ), 119.1 (C-1ꞌ), 117.4 (C-4). Mass (ES): m/z 322.12 
[M+H]+, M.P: 212 0C, Yield: 72 %. 
 
2-{4-[(2-propyl-2H-tetrazol-5-yl)methoxy]phenyl}-1,3-benzoxazole 
(7c): 
IR (KBr): υ 1628 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.72-7.86 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.89-6.98 (m, 4H, 4-
H, 7-H, 3ꞌ-H, 5ꞌ-H) 5.28 (s, 2H, -OCH2), 3.58 (t, 2H, J=7.6Hz, 1ꞌꞌꞌ-CH2), 1.81-
1.92 (m, 2H, 2ꞌꞌꞌ-CH2), 1.11 (t, 3H, J=7.6Hz, 3ꞌꞌꞌ-CH3). 13C-NMR (CDCl3, 
100MHz): δ 161.2 (C-2), 159.2 (C-5ꞌꞌ), 109.3 (C-7), 158.7 (C-4ꞌ), 136.9 (C-
3a), 68.7 (-OCH2), 22.2 (C-5), 56.6 (C-1ꞌꞌꞌ), 120.1 (C-6), 10.4 (C-3ꞌꞌꞌ), 119.2 
(C-1ꞌ), 18.6 (C-4). Mass (ES): m/z 336.21 [M+H]+, M.P: 198 0C, Yield: 72 
%. 
 
2-{4-[(2-butyl-2H-tetrazol-5-yl)methoxy]phenyl}-1,3-benzoxazole 
(7d): 
IR (KBr): υ 1660 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.62-7.74 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.73-6.85 (m, 4H, 4-
H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.24 (s, 2H, -OCH2), 3.46 (t, 2H, J=7.6Hz, 1ꞌꞌꞌ-CH2), 1.76-
1.88 (m, 2H, 2ꞌꞌꞌ-CH2), 1.28-1.39 (m, 2H, 3ꞌꞌꞌ-CH2), 0.94 (t, 3H, J=6.8 Hz, 4ꞌꞌꞌ-
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CH3). 13C-NMR (CDCl3, 100MHz): δ 161.5 (C-2), 159.4 (C-5ꞌꞌ), 158.9 (C-
4ꞌ), 147.96 (C-7a), 137.2 (C-3a), 122.4 (C-5), 120.6 (C-6), 119.2 (C-1ꞌ), 
118.4 (C-4), 113.4 (C-2ꞌ, C-6ꞌ), 112.1 (C-3ꞌ, C-5ꞌ),110.2 (C-7), 68.7 (-
OCH2), 54.8 (C-1ꞌꞌꞌ), 28.4 (C-2ꞌꞌꞌ), 18.6 (C-3ꞌꞌꞌ), 13.9 (C-4ꞌꞌꞌ). Mass (ES): m/z 
350.15 [M+H]+, M.P: 192 0C, Yield: 76 %. 
 
2-(4-{[2-(propan-2-yl)-2H-tetrazol-5-yl]methoxy}phenyl)-1,3-
benzoxazole (7e): 
IR (KBr): υ 1690 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.69-7.77 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.74-6.85 (m, 4H, 4-H, 
7-H, 3ꞌ-H, 5ꞌ-H), 5.28 (s, 2H, -OCH2), 3.88-3.96 (m, 2H, 1ꞌꞌꞌ-CH), 1.84 (d, 
6H, J=7.2Hz, 2ꞌꞌꞌ- (CH3)2). 13C-NMR (CDCl3, 100MHz): δ 161.5 (C-2), 158.6 
(C-5ꞌꞌ), 157.4 (C-4ꞌ), 148.2 (C-7a), 137.9 (C-3a), 122.0 (C-5, C-6), 120.0 
(C-1ꞌ), 118.4 (C-4), 113.8 (C-2ꞌ, C-6ꞌ), 112.4 (C-3ꞌ, C-5ꞌ), 109.6 (C-7), 70.1 
(-OCH2), 63.2 (C-1ꞌꞌꞌ), 25.3 (C-2ꞌꞌꞌ). Mass (ES): m/z 336.08 [M+H]+, M.P: 
202-205 0C, Yield: 65 %. 
 
2-(4-{[2-(2-methylpropyl)-2H-tetrazol-5-yl]methoxy}phenyl)-1,3-
benzoxazole (7f): 
IR (KBr): υ 1683 (C=N of tetrazole) cm-1. 1H-NMR (CDCl3, 
400MHz): δ 7.74-7.88 (m, 4H, 2ꞌ-H, 6ꞌ-H, 5-H, 6-H), 6.88-7.02 (m, 4H, 4-
H, 7-H, 3ꞌ-H, 5ꞌ-H), 5.30 (s, 2H, -OCH2), 1.98-2.09 (m, 2H, 1ꞌꞌꞌ-CH), 1.01 (d, 
6H, J=7.2Hz, 3ꞌꞌꞌ- (CH3)2). 13C-NMR (CDCl3, 100MHz): δ 160.9 (C-2), 158.4 
(C-5ꞌꞌ), 157.9 (C-4ꞌ), 147.6 (C-7a), 137.0 (C-3a), 121.8 (C-5), 120.2 (C-6), 
119.4 (C-1ꞌ), 118.1 (C-4), 114.0 (C-2ꞌ, C-6ꞌ), 112.9 (C-3ꞌ, C-5ꞌ), 109.9 (C-7), 
69.4 (-OCH2), 24.0 (C-2ꞌꞌꞌ), 16.3 (C-3ꞌꞌꞌ). Mass (ES): m/z 350.16 [M+H]+, 
M.P: 206-209 0C, Yield: 65 %. 
 
Antimicrobial screening: 
The synthesized compounds were screened in vitro 
antimicrobial activities using agar well diffusion method. The 
compounds were tested against Gram positive bacteria -Staphylococcus 
aureus and Gram negative bacteria -Pseudomonas aeruginosa and 
Escherichia coli for antibacterial activity and against the fungal species 
Candida albicans, Aspergillus fumigates and Aspergillus niger for 
antifungal activity. The minimum inhibitory concentration (MIC) in 
µg/mL was determined by the serial dilution method. The respective 
test compounds were dissolved in DMSO to obtain 1 mg/mL stock 
solution. Seeded broth (broth containing microbial spores) was 
prepared in nutrient broth (NB) from 24-h-old bacterial cultures on 
nutrient agar at 37 ± 1°C, while fungal spores from 1- to 7-day-old 
Sabouraud agar slant cultures were suspended in Sabouraud dextrose 
broth (SDB). The number of colony forming units (cfu) of the seeded 
broth were determined by the plating technique, and adjusted in the 
range of 104-105 cfu/mL. The final inoculum size was 105 cfu/mL for the 
antibacterial assay and 1.1-1.5× 102 for the antifungal assay. Testing was 
performed at pH 7.4 ± 0.2 for bacteria (NB) and at pH 5.6 for fungi 
(SDB). Exactly 0.4 mL of the solution of the test compound was added to 
1.6 mL of seeded broth to form the first dilution. One milliliter of this 
was diluted with a further 1 mL of seeded broth to give the second 
dilution, and so on, till six such dilutions were obtained. A set of assay 
tubes containing only seeded broth were kept as control. The tubes 
were incubated in BOD (biochemical oxygen demand) incubators at 37 ± 
1°C for bacteria and 28 ± 1°C for fungi. The MICs were recorded by 
visual observation after 24 h (for bacteria) and 72–96 h (for fungi) of 
incubation. Ciprofloxacin was used as the standard for bacterial studies 
and Fluconazole as the standard drug for fungal studies. 
Molecular Docking Studies: 
 To investigate the binding pattern of the synthesized 
compounds respect to their binding affinity, docking experiments were 
performed using Discovery Studio. Molecular docking is a technique 
which serves to verify binding integrity and interaction poses of ligands 
within the binding pocket of target proteins. To validate and specify the 
target for anti-fungal and anti-bacterial activity of newly synthesized 
compounds, target proteins i.e., biotin protein ligase (BPL) (3V7R) from 
Staphylococcus aureus and dihydrofolate reductase (DHFR) (PDB ID 
4HOF) from C. albicans were selected as bacterial and fungal target.  
                  The bacterial drug target BPL catalyzes the ATP-dependent 
addition of biotin onto specific carboxylases that require the cofactor for 
activity. The BPL in S. aureus (SaBPL) has two such substrates, acetyl-
CoA carboxylase and pyruvate carboxylase that without biotinylation 
are totally inactive. BPL as a potential antibacterial target, as acetyl-CoA 
carboxylase is required for membrane lipid biosynthesis (9-11). This 
metabolic pathway is important in S. aureus, as the bacteria can only 
derive 50% of their membrane phospholipids from exogenous fatty 
acids.  
 The fungal target, Dihydrofolate reductase (DHFR) catalyzes 
the reaction of 7,8-dihydrofolate and NADPH to form 5,6,7,8-
tetrahydrofolate and NADP+. Tetrahydrofolate is essential for the 
biosynthesis of purines, thymidylate, and several amino acids. Because 
of its metabolic importance, DHFR has been extensively studied as 
targets for many diseases. 
Preparation of the proteins: 
The structures of target proteins i.e., biotin protein ligase 
(BPL) (3V7R) from Staphylococcus aureus and dihydrofolate reductase 
(DHFR) (PDB ID 4HOF) from C. albicans, are retrieved from the PDB 
database. After importing in to the Discovery Studio 2.5 (DS), using the 
clean Protein protocol, the proteins are prepared for correcting the lack 
of hydrogen atoms, missing atoms and residues, incorrect atom order in 
amino acids, protonation states of ionizable side-chains and terminal 
groups by using predicted pKs, to complete the protein chain. Water 
molecules and all the hetero atoms are removed and CHARMm force 
field is applied for energy minimization using different algorithms till 
the protein reaches a convergence gradient 0.001 kcal/mol. After energy 
minimization, the binding pockets of the receptor are predicted by the 
receptor cavity method (Eraser algorithm).  Using Define and Edit 
Binding Site tools in DS, the binding site of the target proteins is 
determined based on the occupied volume of the known ligands in the 
active site. The ligand is first selected and a sphere is created around the 
residues comprising binding site at a radius of 9 Å using define sphere 
from the selection option. 
Ligand generation and optimization: 
Using ACD/ ChemSketch (12.0) the 2D structures of all the 
synthesized compounds are drawn and saved in mol file format. These 
saved compounds are later imported in to DS and ligand preparation 
with constraint parameters such as consistency of ionization states, 
tautomer and isomer generation, removal of duplicate structures, 
conversion of 2D to 3D structures using catalyst algorithm is done and 
are energy minimized until a convergence gradient of 0.001 k.cal/ mol is 
reached. 
Docking strategy: 
 The docking program LibDock module in Discovery Studio 
have been employed to generate the bioactive binding poses of 
synthesized compounds in the active site of protein. LibDock uses 
protein site features called HotSpots” that are resolved with a grid fixed 
in active site which counts the hotspot map for polar and apolar cluster 
and further used for the alignment of the ligand conformations to the 
protein interaction sites. All other docking and consequent scoring 
parameters used were kept at their default settings. Finally, at the end of 
the docking process, it returns all the minimized ligand poses and their 
rankings. Among all the obtained poses of each ligand, the ligand 
binding in a receptor cavity is evaluated based on the LibDock top score, 
which uses a simple pair-wise method. The ligands with high LibDock 
scores are preferred for estimating binding energies of the protein-
ligand complex. The complex pose with the best binding energy is used 
for further binding mode analysis. In addition, all docked poses were 
scored by applying Analyze Ligand Poses sub protocol in Discovery 
Studio. 
RESULTS AND DISCUSSION 
Antibacterial activity and Antifungal activity: 
 The synthesized compounds were assessed to elicit there in 
vitro antibacterial activity against Staphylococcus aureus, Pseudomonas 
aeruginosa and Escherichia coli and were found to possess activities 
against the microorganisms.  The antibacterial potency of the 
synthesized compounds was compared with Ciprofloxacin using their 
minimum inhibitory concentration (MIC) values that are summarized in 
table-1. According to the observed MIC values, all the compounds 
exhibited moderate to good bacterial inhibition against all the tested 
bacterial strains. Among the synthesized compounds it was clear that 
compound 7d and 6b showed very good antibacterial activity against all 
the bacterial strains. Compound 7d exhibited maximum inhibition 
activity against S. aureus and E. coli with a MIC value of 16µg/ml and 
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10µg/ml respectively and compound 6b showed maximum inhibition 
against Pseudomonas aeruginosa with a MIC value of 7µg/ml. 
 In vitro antifungal activity against Candida albicans, 
Aspergillus fumigates and Aspergillus niger. The antifungal potency of the 
synthesized compounds was compared with Fluconazole using their 
minimum inhibitory concentration (MIC) values that are summarized in 
table-1. The results indicate that compound 7b has excellent antifungal 
activity against Aspergillus fumigates and Candida albicans with a MIC 
value of 18µg/ml and 12µg/ml respectively. And against the Aspergillus 
niger, compound 6c showed maximum inhibition with a MIC value of 16 
µg/ml. 
Table No. 1: In vitro antimicrobial activity and docking scores of the top ranked poses of the synthesized triazole (6a-f) and tetrazole (7a-f) 
derivatives 
 Minimum inhibitory concentration (MIC) in µg/mL LibDock score 
 
 
Compound 
Anti-microbial activity Anti-fungal activity BPL DHFR 
Staphylococcus 
aureus 
Pseudomonas 
aeruginosa 
Escherichia 
coli. 
Aspergillus 
fumigates 
Aspergillus 
niger 
Candida 
albicans 
Staphylococcus 
aureus 
Candida 
albicans 
6a 17 17 19 22 23 15 121.721 129.801 
6b 16 7 11 24 36 32 125.683 129.945 
6c 34 18 26 21 16 18 130. 398 138.163 
6d 31 16 28 19 15 21 130. 769 142.376 
6e 20 26 31 41 46 54 123.453 133.124 
6f 28 31 31 18 27 12 125.215 133.254 
7a 22 31 56 25 54 57 113.845 128.215 
7b 16 16 10 33 45 31 117.443 138.207 
7c 20 19 15 31 48 23 120.737 131.851 
7d 22 28 23 27 40 21 126.884 135.551 
7e 27 25 19 20 29 19 122.737 133.629 
7f 28 15  24 23 18 135.378 140.959 
Standard         120     126   
 
Docking Studies: 
The antimicrobial potency of all the newly synthesized 
compounds were subjected for further docking studies to explore the 
binding pattern against biotin protein ligase (BPL) (3V7R) from 
Staphylococcus aureus and dihydrofolate reductase (DHFR) (PDB ID 
4HOF) from C. albicans. 
 Conformational search of these ligands along with the 
standard drugs ciproflaxacin against bacterial and fluconazole against 
fungal were investigated via Libdock program of DS. In this study, ten 
conformers were generated for each ligand producing their 
corresponding docking scores using default parameters. Of all the 
conformations generated for each compound, the compound with the 
highest LibDock score is taken for interaction analysis of the hydrogen 
bonding. The Summary of docking scores of the top ranked poses of 
each compound are tabulated in Table-1.  
                       From the observed docking results, almost all the 
compounds exhibited better binding affinity with both of the protein 
targets. Docking analysis of synthesized triazole compounds revealed 
that the compound 3d fitted well in the active site of the bacterial target 
BPL and fungal target DHFR showing the best docking scores of 130.769 
and 142.376 respectively. The best conformation with H-bond 
interactions obtained for these compounds is shown in figure 1.  From 
the Figure 1a it is revealed that three hydrogen bonds are formed with 
the protein BPL and compound 6d.   A hydrogen bond is formed 
between the hydrogen atom of the amino acid Arginine122 and 16th 
oxygen atom of compound 7(AA: Arg122:HN-Comp6d: O16) with a 
hydrogen bond distance of 2.333 Å .  The second hydrogen bond is 
formed between the hydrogen atom of Arginine125 and 21 nitrogen 
atom of compound 6d (AA: Arg125:HN-Comp6d: N21) with a hydrogen 
bond distance of 1.984 Å.  Third hydrogen bond is formed between the 
hydrogen atom of Arginine125 and 20th nitrogen atom of compound 7 
(AA: Arg125:HN-Comp6d: N20) with a hydrogen bond distance of 1.737 
Å.  Some close contacts are also formed between the protein and the 
compound 6d that   is formed with hydrogen atom of the compound 6d 
and the hydrogen atom of the amino acid threonine94 (Comp6d:H30-A: 
Thr94:HG1) with a distance of 1.737 Å. 
 From the Figure 1 (b) it is revealed that two hydrogen bonds 
are formed with the protein DHFR and compound 6d.   A hydrogen bond 
is formed between the hydrogen atom of the amino acid Tyrosine118 
and oxygen atom of compound 6d (AA: Tyr118: OH-O2:Comp6d) with a 
hydrogen bond distance of 2.125 Å .  The second hydrogen bond is 
formed between the hydrogen atom of Valine10 and oxygen atom of 
compound 7 (AA: Val10:HN-O1:Comp6d) with a hydrogen bond distance 
of 2.098 Å.  Close contact is formed with oxygen atom of the compound 
6d and the hydrogen atom of the amino acid glutamine (Comp6d:O-
HG1:Glu32) with a distance of 1.689 Å. 
  
a. BPL      b. DHFR 
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c. BPL      d. DHFR 
Fig. 1: Hydrogen bond interactions of compound 6d with a. BPL and b. DHFR, 7f with c. BPL and d. DHFR  
Docking analysis of synthesized tetrazole compounds 
revealed that the compound 7f fitted well in the active site of the 
bacterial target BPL and fungal target DHFR showing the high docking 
scores of 135.378 and 140.959 respectively. The hydrogen bond 
interaction of the proteins and the compound 7f are shown in figure 1. 
From the Figure c it is revealed that two hydrogen bonds are formed 
with the protein BPL and compound 7f. A hydrogen bond is formed 
between the hydrogen atom of the amino acid Argine125 and nitrogen 
atom of compound 7f (AA: Arg125:HH11- Comp7f: N21) with a 
hydrogen bond distance of 2.121 Å .  The second hydrogen bond is 
formed between the hydrogen atom of Argine122 and nitrogen atom of 
compound 7f (AA: Arg122:HN-Comp7f: N21) with a hydrogen bond 
distance of 2.118 Å.  Close contact is formed with oxygen atom of the 
compound 4f and the hydrogen atom of the amino acid glutamine 
(Comp7f: O-HG1:Glu32) with a distance of 1.689 Å. Some close contacts 
are also formed between the protein and the compound 7f. They are 
formed with hydrogen atom of the compound 7f and the hydrogen atom 
of the amino acid threonine94 (Comp7f:H30-A: Thr94:HG1) and other 
with the compound 7f and the hydrogen atom of the amino acid 
Serine128 with a distances of 1.742 Å and 1.713 Å respectively. 
From the Figure 1d it is revealed that two hydrogen bonds 
are formed with the protein DHFR and compound 7f.   A hydrogen bond 
is formed between the hydrogen atom of the amino acid Alanine11 and 
oxygen atom of compound 7f (AA: Ala11:HN-Comp7f: O16) with a 
hydrogen bond distance of 2.228 Å.  The second hydrogen bond is 
formed between the oxygen atom of glutamine and hydrogen atom of 
compound 7f (AA: GLu32:OE1-Comp7f:H39) with a hydrogen bond 
distance of 1.879 Å.  Some close contacts are also formed between the 
protein and the compound 7f. They are formed with hydrogen atom of 
the compound 4f and the hydrogen atom of the amino acid tyrosine118 
(Comp7f:H36-A: Tyr118: HH) and other with the amino acid Valine10 
and the hydrogen atom of compound 7f with a distances of 1.685 Å and 
1.645 Å respectively. 
CONCLUSION 
A new series of novel triazole (6a-f) and tetrazole (7a-f) 
have been synthesized and evaluated for them in vitro antibacterial and 
antifungal activities. The antimicrobial activity results indicated that 
some of the tested compounds showed the most promising antibacterial 
and antifungal activities. All the molecules were studied for their 
interactions with the bacterial target BPL and fungal target DHFR 
enzymes by molecular docking protocol. Among the tested molecules, 
compound 6d and 7f exhibited good docking scores of 130.769 and 
135.378 against bacterial target and 142.376 and 140.959 against fungal 
target. The results of antimicrobial activity are supported by docking 
analysis. These observations may promote a further development of our 
research in this field. 
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